γ-Globulin levels in patients with community-acquired septic shock

Shock

Volumn 32, Issue 4, 2009, Pages 379-385

  Taccone, Fabio Silvio ^a   Stordeur, Patrick ^a   De Backer, Daniel ^a   Creteur, Jacques ^a   Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Free light chains; Immunoglobulins; Outcome; Sepsis

Indexed keywords

HYPERTENSIVE FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; MALE; MORTALITY; SEPTIC SHOCK; TREATMENT OUTCOME;

AGED; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; GAMMA-GLOBULINS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESPIRATORY DISTRESS SYNDROME, ADULT; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS;

EID: 70349660078     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181a2c0b2     Document Type: Article

References (62)

1. Vincent JL, Taccone F, Schmit X: Classification, incidence, and outcomes of sepsis and multiple organ failure. Contrib Nephrol 156:64-74, 2007.
2. Vincent JL, Sun Q, Dubois MJ: Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 34:1084-1093, 2002.
3. Mouthon L, Lortholary O: Intravenous immunoglobulins in infectious diseases: where do we stand? Clin Microbiol Infect 9:333-338, 2003.
4. Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, Cameron DW, Hebert PC: Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 146:193-203, 2007.
5. Kreymann KG, de Heer G, Nierhaus A, Kluge S: Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 35:2677-2685, 2007.
6. Laupland KB, Kirkpatrick AW, Delaney A: Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 35:2686-2692, 2007.
7. Pildal J, Gotzsche PC: Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 39:38-46, 2004.
8. Rodriguez A, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, Palizas F: Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock 23:298-304, 2005.
9. Koleba T, Ensom MH: Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy 26:813-827, 2006.
10. Neilson AR, Burchardi H, Schneider H: Cost-effectiveness of immunoglobulin MYenriched immunoglobulin (pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care 20:239-249, 2005.
11. Werdan K: Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins. Ther Apher 5:115-122, 2001.
12. Goldammer A, Derfler K, Herkner K, Bradwell AR, Horl WH, Haas M: Influence of plasma immunoglobulin level on antibody synthesis. Blood 100:353-355, 2002.
13. Taccone F, De Backer D, Creteur J, Vincent JL: Gammaglobulin levels in patients with septic shock. Crit Care Med 35:A266, 2007 (abstract).
14. LevyMM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250-1256, 2003.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 13:818-829, 1985.
16. Vincent JL, Moreno R, Takala J, Willatts S, de Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 22:707-710, 1996.
17. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818-824, 1994.
18. Malbrain ML, Debaveye Y, De Coninck J, Delmarcelle D: Capillary leakage index as outcome predictor? Intensive Care Med 27:S229, 2001 (abstract).
19. McPherson RA, Pincus MR: Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. Philadelphia, PA: W.B. Saunders, 2007.
20. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R: Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47:673-680, 2001.
21. Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 365:63-78, 2005.
22. Stoica G, Macarie E, Michiu V, Stoica RC: Biologic variation of human immunoglobulin concentration. I Sex-age specific effects on serum levels of IgG, IgA, IgM and IgD. Med Interne 18:323-332, 1980.
23. Veys EM, Wieme RJ, Van Egmond J, Gabriel P, van der JJ: Short term variation of human immunoglobulin levels with an estimation of the day to day physiological variability. Clin Chim Acta 75:275-285, 1977.
24. Levinson SS, Keren DF: Free light chains of immunoglobulins: clinical laboratory analysis. Clin Chem 40:1869-1878, 1994.
25. Charlton B, Schindhelm K: The effect of extracorporeal antibody removal on antibody synthesis and catabolism in immunized rabbits. Clin Exp Immunol 60:457-464, 1985.
26. Charlton B, Schindhelm K, Smeby LC, Farrell PC: Analysis of immunoglobulin G kinetics in the non-steady state. J Lab Clin Med 105:312-320, 1985.
27. Petras G, Meretey K: Serum IgG, IgA and IgM changes during infectious complications induced by facultative pathogenic gram-negative bacteria. Zentralbl Bakteriol [Orig A] 245:96-105, 1979.
28. Goldie AS, Fearon KC, Ross JA, Barclay GR, Jackson RE, Grant IS, Ramsay G, Blyth AS, Howie JC: Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Spsis Intervention Group. JAMA 274:172-177, 1995.
29. Bennett-Guerrero E, Barclay GR, Weng PL, Bodian CA, Feierman DE, Vela- Cantos F, Mythen MG: Endotoxin-neutralizing capacity of serum from cardiac surgical patients. J Cardiothorac Vasc Anesth 15:451-454, 2001.
30. Hack CE, Zeerleder S: The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 29:S21YS27, 2001.
31. Suba EA, McKenna TM, Williams TJ: In vivo and in vitro effects of endotoxin on vascular responsiveness to norepinephrine and signal transduction in the rat. Circ Shock 36:127-133, 1992.
32. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 342:1334-1349, 2000.
33. Arif SK, Verheij J, Groeneveld AB, Raijmakers PG: Hypoproteinemia as a marker of acute respiratory distress syndrome in critically ill patients with pulmonary edema. Intensive Care Med 28:310-317, 2002.
34. Margarson MP, Soni NC: Changes in serum albumin concentration and volume expanding effects following a bolus of albumin 20% in septic patients. Br J Anaesth 92:821-826, 2004.
35. McCuskey RS, Nishida J, McDonnell D, Baker GL, Urbaschek R, Urbaschek B: Effect of immunoglobulin G on the hepatic microvascular inflammatory response during sepsis. Shock 5:28-33, 1996.
36. Wenisch C, Parschalk B, Patruta S, Brustbauer R, Graninger W: Effect of polyclonal immunoglobulins on neutrophil phagocytic capacity and reactive oxygen production in patients with gram-negative septicemia. Infection 27:183-186, 1999.
37. Schedel I, Dreikhausen U, Nentwig B, Hockenschnieder M, Rauthmann D, Balikcioglu S, Coldewey R, Deicher H: Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 19:1104-1113, 1991.
38. Dominioni L, Bianchi V, Imperatori A, Minoia G, Dionigi R: High-dose intravenous IgG for treatment of severe surgical infections. Dig Surg 13: 430-434, 1996.
39. Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, Ubelacker R, Buchheidt D, Behre G, Hiddemann W, et al.: IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 34: 1319-1325, 2006.
40. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, Viell B, Marget W, Seewald M, Walger P, et al.: Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 35: 2693-2701, 2007.
41. Jesdinsky HJ, Tempel G, Castrup HJ, Seifert J: Cooperative Group of Additional Immunoglobulin Therapy in Severe Bacterial Infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis. Klin Wochenschr 65:1132-1138, 1987.
42. Masaoka T, Hasegawa H, Takazu F: The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Jpn J Chemother 48:199-217, 2000.
43. Alejandria MM, Lansang MA, Dans LF, Mantaring JB: Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev CD001090, 2002.
44. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:296-327, 2008.
45. Kawut SM, Shah L, Wilt JS, Dwyer E, Maani PA, Daly TM, O'Shea MK, Sonett JR, Arcasoy SM: Risk factors and outcomes of hypogammaglobulinemia after lung transplantation. Transplantation 79:1723-1726, 2005.
46. Pilz G, Appel R, Kreuzer E, Werdan K: Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis. Chest 111:419-426, 1997.
47. Werdan K, Pilz G, Muller-Werdan U, Maas EM, Schmitt DV, Mohr FW, Neeser G, Schondube F, Schafers HJ, Haverich A, et al.: Immunoglobulin G treatment of postcardiac surgery patients with score-identified severe systemic inflammatory response syndromeVthe ESSICS study. Crit Care Med 36: 716-723, 2008.
48. Christensson B, Johansson PJ, Oxelius VA: Imbalanced serum IgG subclass pattern in toxic shock syndrome patients: deficiency of specific IgG1 and IgG4 subclass antibodies to toxic shock syndrome toxin 1. Clin Exp Immunol 66:443-449, 1986.
49. Norrby-Teglund A, Ihendyane N, Darenberg J: Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis 35:683-689, 2003.
50. Yamani MH, Chuang HH, Ozduran V, Avery RK, Mawhorter SD, Cook DJ, Zilka C, Zeroske K, Buda T, Hobbs RE, et al.: The impact of hypogammaglobulinemia on infection outcome in patients undergoing ventricular assist device implantation. J Heart Lung Transplant 25:820-824, 2006.
51. Goldfarb NS, Avery RK, Goormastic M, Mehta AC, Schilz R, Smedira N, Pien L, Haug MT, Gordon SM, Hague LK, et al.: Hypogammaglobulinemia in lung transplant recipients. Transplantation 71:242-246, 2001.
52. Ekdahl K, Rollof J, Oxelius VA, Engellau J, Braconier JH: Analysis of immunoglobulin isotype levels in acute pneumococcal bacteremia and in convalescence. Eur J Clin Microbiol Infect Dis 13:374-378, 1994.
53. Moran K, Munster AM: Alterations of the host defense mechanism in burned patients. Surg Clin North Am 67:47-56, 1987.
54. Glinz W, Grob PJ, Nydegger UE, Ricklin T, Stamm F, Stoffel D, Lasance A: Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. A randomized, placebo-controlled study. Intensive Care Med 11:288-294, 1985.
55. Kress HG, Scheidewig C, Schmidt H, Silber R: Reduced incidence of postoperative infection after intravenous administration of an immunoglobulin AY and immunoglobulin MYenriched preparation in anergic patients undergoing cardiac surgery. Crit Care Med 27:1281-1287, 1999.
56. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862-871, 2002.
57. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez- Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001.
58. McGowan JE Jr, Barnes MW, Finland M: Bacteremia at Boston City Hospital: occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J Infect Dis 132:316-335, 1975.
59. Ito Y, Lukita-Atmadja W, Machen NW, Baker GL, McCuskey RS: High doses of intravenous immunoglobulin G enhance Kupffer cell phagocytic function during the late phase of sepsis and endotoxemia in rats. Shock 13:485-491, 2000.
60. Goldstein MF, Goldstein AL, Dunsky EH, Dvorin DJ, Belecanech GA, Shamir K: Selective IgM immunodeficiency: retrospective analysis of 36 adult patients with review of the literature. Ann Allergy Asthma Immunol 97:717-730, 2006.
61. Herrod HG: Clinical significance of IgG subclasses. Curr Opin Pediatr 5:696-699, 1993.
62. Ochs HD, Stiehm ER, Winkelstein JA: Antibody deficiencies. In: Stiehm ER, Ochs HD, Winkelstein JA, (eds.): Immunologic Disorders in Infants and Children. Philadelphia, PA: Elsevier, 356-426, 2004.